Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tracked since FDA approval last December – but how are physicians based in the EU5 utilising the product?
FirstWord is polling gastroenterologists/hepatologists and infectious disease specialists based in France, Germany, Italy, Spain and the UK this week to ascertain how easily physicians are able to access Sovaldi and in what patients/treatment regimens they are most frequently using Gilead's product.
While both strong uptake for Sovaldi and vocal opposition from payers has shaped the launch narrative for this drug in the US (see also - Physician Views Poll Results: Gilead's all-oral hepatitis C combo launch poised to better Sovaldi US debut despite payer scrutiny) its European performance has been less focused on.
The potential significance of the European market was highlighted late last week when Bristol-Myers Squibb's daclatasvir was recommended for approval in the region. Due to become available some months ahead of Gilead's own Sovaldi/ledipasvir combination, Merck's product is likely to benefit from some uptake in combination with Sovaldi, argue analysts at Bloomberg Industries.
Whether this is sustainable once Gilead's fixed-dose combination, or AbbVie's all-oral offering, launches is conjecture. However, more nuanced access challenges in Europe are likely to shape the competitive environment for next-generation hepatitis C therapies over the next few years.
With this in mind, FirstWord's latest Physician Views poll looks to provide greater insight into the launch of Sovaldi to date in the EU5. Specifically we are asking physicians...
How they describe their access to Sovaldi to date?
What percentage of total hepatitis C patients they have treated in 2014 have received Sovaldi in some capacity?
What patient genotype they are treating most frequently with Sovaldi...
...and for this patient genotype in what regimen they are using Sovaldi most frequently?
What percentage of hepatitis C patients (irrespective of genotype) they are currently warehousing for treatment with an all-oral and interferon/ribavirin- sparing regimen?
You will be able to read the results and analysis on Wednesday.
Results and related analysis will be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
Note: FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialities and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at email@example.com.
To read more Physician Views articles, click here.